BACKGROUND: Early detection and confirmation of cholera outbreaks are crucial for rapid implementation of control measures.
BACKGROUND: Human African trypanosomiasis is fatal without treatment. The long post-treatment follow-up (24 months) required to assess cure complicates patient management and is a major obstacle in the development of new therapies.
BACKGROUND: In 2005, the Democratic Republic of Congo (DRC) adopted artesunate and amodiaquine (ASAQ) as first-line anti-malarial treatment.
BACKGROUND: In 2008, Africa accounted for 94% of the cholera cases reported worldwide.
BACKGROUND: Data on efficacy of artemisinin-based combination therapy (ACT) to treat Plasmodium falciparum during pregnancy in sub-Saharan Africa is scarce.
BACKGROUND: Data from the largest randomized, controlled trial for the treatment of children hospitalized with severe malaria were used to identify such predictors of a poor outcome from severe malaria.
Improved laboratory diagnosis is critical to reduce the burden of malaria in pregnancy.
In Africa, although emergence of multidrug-resistant (MDR) tuberculosis (TB) represents a serious threat in countries severely affected by the HIV epidemic, most countries lack drug-resistant TB data.
Measles epidemics in West Africa cause a significant proportion of vaccine-preventable childhood mortality.
Providing abandoned children the necessary medical and psychological care as possible after their institutionalization may minimize developmental delays.
